Upstream Bio, Inc. (NASDAQ:UPB) Receives $39.00 Average PT from Brokerages

Shares of Upstream Bio, Inc. (NASDAQ:UPB) have received an average recommendation of “Moderate Buy” from the five brokerages that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $39.00.

Several research firms have issued reports on UPB. Weiss Ratings reissued a “sell (d-)” rating on shares of Upstream Bio in a research report on Wednesday, January 21st. Wall Street Zen cut shares of Upstream Bio from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Finally, Evercore cut shares of Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 price objective for the company. in a research report on Friday, March 27th.

Institutional Investors Weigh In On Upstream Bio

Several large investors have recently added to or reduced their stakes in UPB. GF Fund Management CO. LTD. purchased a new stake in Upstream Bio in the 4th quarter valued at about $29,000. Torren Management LLC purchased a new stake in shares of Upstream Bio in the 4th quarter worth approximately $30,000. BNP Paribas Financial Markets lifted its position in shares of Upstream Bio by 229.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company’s stock worth $34,000 after purchasing an additional 2,158 shares during the period. Legal & General Group Plc lifted its position in shares of Upstream Bio by 83.0% in the 2nd quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock worth $35,000 after purchasing an additional 1,440 shares during the period. Finally, Empowered Funds LLC purchased a new stake in shares of Upstream Bio in the 4th quarter worth approximately $45,000.

Upstream Bio Price Performance

Upstream Bio stock opened at $9.30 on Wednesday. The stock has a market cap of $506.11 million, a price-to-earnings ratio of -3.48 and a beta of 1.80. Upstream Bio has a 1 year low of $7.25 and a 1 year high of $33.68. The firm has a 50-day moving average of $8.96 and a two-hundred day moving average of $20.27.

Upstream Bio (NASDAQ:UPB) last released its quarterly earnings data on Thursday, March 26th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.06). The company had revenue of $0.67 million during the quarter, compared to analysts’ expectations of $0.52 million. Upstream Bio had a negative net margin of 5,026.03% and a negative return on equity of 36.48%. Research analysts expect that Upstream Bio will post -3.02 earnings per share for the current year.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.